Management Update

Alliance Pharma PLC

08 May 2024

 

For immediate release

8 May 2024

ALLIANCE PHARMA

("Alliance", "Company" or the "Group")

Management update

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that Peter Butterfield, Chief Executive Officer ("CEO"), has decided to leave the business in order to pursue other business interests. Following a comprehensive search process, Nick Sedgwick has been appointed as the new CEO, starting 13 May 2024. Peter will remain at Alliance until 30 June 2024 to facilitate a thorough handover.

Peter joined the Board of Alliance in 2010 and became CEO in 2018, driving a strategy to increase the focus on consumer healthcare and extending the Company's global reach into APAC and the US.

Nick Sedgwick brings thirty years of consumer health experience across European, US and global roles at major multinational companies such as Reckitt, Coty and Nestlé. Most recently Nick was Regional Director for UK and Ireland Consumer Health at Reckitt during which time he increased revenue and improved profitability in the second largest market for the company. Prior to this, Nick worked at Coty holding a number of senior roles including Senior Vice President for Global Sales and Commercial Capabilities, Senior Vice President Sales for the US business and General Manager Consumer Beauty for UK and Ireland. Throughout his career, Nick has worked in multiple countries, always delivering high revenue growth through consumer-centric strategies, high performance teams and excellence in execution.

Camillo Pane, Chair of Alliance, said:

"The Board and I would like to thank Peter for everything that he has done for Alliance. He led Alliance's transition towards Consumer Healthcare and Group revenues have almost doubled since he became CEO. We wish Peter well in his future endeavours.

"We welcome Nick to Alliance and look forward to working with him as he leads the Company through the next phase of its growth and development."

Peter Butterfield, Chief Executive Officer of Alliance, said:

"It has been a genuine privilege to lead Alliance over the last six years through a period of growth and transformation. I am very confident that the Company is in good hands and look forward to seeing it go from strength to strength."

Nick Sedgwick, Chief Executive Officer designate of Alliance, said:

"I am really excited to be joining Alliance at such an important time for the business. I look forward to getting to know the Company in depth over the next few months and working with the management team to deliver the next phase of growth."

In accordance with Schedule 2 (g) of the AIM Rules for Companies, Nicholas John Sedgwick (aged 51 years) holds/has held the following directorships/partnerships in the last five years:

Current directorships/partnerships	Previous directorships/partnerships (last five years)
None	RB UK Commercial Limited Proprietary Association of Great Britain Cosmetic, Toiletry and Perfumery Association Limited

Mr Sedgwick currently holds no ordinary shares in the Company.

There are no further disclosures to made be under Schedule 2(g) of the AIM Rules for Companies.

For further information:

Alliance Pharma plc	+ 44 (0)1249 466966
Cora McCallum, Head of Investor Relations & Corporate Communications	+ 44 (0)1249 705168
[e-mail]
Buchanan	+ 44 (0)20 7466 5000
Mark Court / Sophie Wills
[e-mail]
Deutsche Numis (Nominated Adviser and Joint Broker)	+ 44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Sher Shah
Investec Bank plc (Joint Broker)	+ 44 (0)20 7597 5970
Patrick Robb / Lydia Zychowska

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

 

END